Century Therapeutics Inc
NASDAQ:IPSC
Income Statement
Earnings Waterfall
Century Therapeutics Inc
Income Statement
Century Therapeutics Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
2
+132%
|
5
+90%
|
5
+11%
|
6
+13%
|
5
-22%
|
2
-45%
|
2
-10%
|
1
-39%
|
2
+49%
|
3
+31%
|
7
+145%
|
115
+1 644%
|
114
-1%
|
113
-1%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(49)
|
(62)
|
(69)
|
(82)
|
(95)
|
(105)
|
(115)
|
(123)
|
(129)
|
(134)
|
(133)
|
(130)
|
(127)
|
(147)
|
(131)
|
(134)
|
(140)
|
(148)
|
(147)
|
(136)
|
|
| Selling, General & Administrative |
(10)
|
(10)
|
(12)
|
(16)
|
(19)
|
(24)
|
(28)
|
(30)
|
(32)
|
(33)
|
(33)
|
(34)
|
(35)
|
(35)
|
(35)
|
(34)
|
(33)
|
(33)
|
(32)
|
(31)
|
|
| Research & Development |
(40)
|
(47)
|
(58)
|
(66)
|
(76)
|
(81)
|
(87)
|
(93)
|
(97)
|
(101)
|
(99)
|
(96)
|
(93)
|
(91)
|
(96)
|
(100)
|
(107)
|
(110)
|
(110)
|
(105)
|
|
| Other Operating Expenses |
0
|
(5)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(21)
|
0
|
0
|
0
|
(5)
|
(4)
|
0
|
|
| Operating Income |
(49)
N/A
|
(62)
-26%
|
(69)
-12%
|
(82)
-18%
|
(95)
-15%
|
(104)
-10%
|
(113)
-8%
|
(119)
-5%
|
(124)
-4%
|
(128)
-4%
|
(128)
+0%
|
(128)
+0%
|
(125)
+2%
|
(145)
-16%
|
(128)
+12%
|
(131)
-2%
|
(134)
-2%
|
(33)
+75%
|
(33)
+1%
|
(23)
+30%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
12
|
7
|
10
|
14
|
13
|
12
|
11
|
9
|
|
| Non-Reccuring Items |
(5)
|
0
|
0
|
0
|
0
|
(10)
|
(10)
|
(10)
|
(10)
|
0
|
(4)
|
(8)
|
(21)
|
0
|
(17)
|
(13)
|
(4)
|
0
|
0
|
(11)
|
|
| Total Other Income |
1
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
4
|
7
|
9
|
11
|
(0)
|
6
|
3
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(54)
N/A
|
(62)
-16%
|
(70)
-13%
|
(83)
-18%
|
(96)
-15%
|
(115)
-20%
|
(123)
-7%
|
(127)
-4%
|
(131)
-3%
|
(123)
+6%
|
(125)
-1%
|
(126)
-1%
|
(135)
-7%
|
(133)
+2%
|
(131)
+1%
|
(131)
+1%
|
(125)
+4%
|
(20)
+84%
|
(22)
-8%
|
(25)
-15%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(2)
|
(3)
|
(2)
|
(1)
|
0
|
1
|
(2)
|
(2)
|
0
|
(2)
|
|
| Income from Continuing Operations |
(54)
|
(62)
|
(70)
|
(83)
|
(96)
|
(115)
|
(123)
|
(127)
|
(131)
|
(125)
|
(127)
|
(129)
|
(137)
|
(133)
|
(131)
|
(130)
|
(127)
|
(22)
|
(23)
|
(26)
|
|
| Net Income (Common) |
(54)
N/A
|
(62)
-16%
|
(70)
-13%
|
(83)
-18%
|
(96)
-15%
|
(115)
-20%
|
(123)
-7%
|
(127)
-4%
|
(131)
-3%
|
(125)
+5%
|
(127)
-2%
|
(129)
-2%
|
(137)
-6%
|
(133)
+2%
|
(131)
+2%
|
(130)
+1%
|
(127)
+2%
|
(22)
+83%
|
(23)
-7%
|
(26)
-14%
|
|
| EPS (Diluted) |
-7.16
N/A
|
-8.1
-13%
|
-5.83
+28%
|
-1.52
+74%
|
-2.96
-95%
|
-2.01
+32%
|
-2.12
-5%
|
-2.19
-3%
|
-2.27
-4%
|
-2.14
+6%
|
-2.16
-1%
|
-2.18
-1%
|
-2.3
-6%
|
-2.15
+7%
|
-1.59
+26%
|
-1.53
+4%
|
-1.61
-5%
|
-0.25
+84%
|
-0.28
-12%
|
-0.31
-11%
|
|